Peripheral-type small cell lung cancer is associated with better survival and higher frequency of interstitial lung disease

Kanaji, Nobuhiro; Sakai, Kenichiro; Ueda, Yutaka; Mikami, Hiroshi; Ishii, Tomoya; Watanabe, Naoki; Kita, Nobuyuki; Kadota, Kyuichi; Kadowaki, Norimitsu; Bandoh, Shuji

doi:10.1016/j.lungcan.2017.03.013

Cited by 28 publications

(40 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…OS was significantly shorter in adenocarcinoma patients with ILD than in those without ILD (median 267 vs 539 days, respectively), and the presence of ILD was an independent poor prognostic factor for OS, which is consistent with findings of previous reports. 18 – 20 …”

Section: Discussionmentioning

confidence: 99%

Clinical features of patients with lung cancer accompanied by thromboembolism or disseminated intravascular coagulation

Kanaji

Mizoguchi

Inoue

et al. 2018

TCRM

Self Cite

View full text Add to dashboard Cite

PurposeThromboembolism (TE) and disseminated intravascular coagulation (DIC) are often present concomitantly. This study aimed to investigate the clinical features of patients with lung cancer and TE and/or DIC.Patients and methodsData on 716 patients with pathologically confirmed diagnoses of lung cancer were retrospectively analyzed for TE/DIC.ResultsTE was identified in 16 patients (2.2%) and DIC was identified in 5 (0.7%) during the diagnosis of cancer. TE was more often observed in adenocarcinoma (4.0%). Both TE and DIC were more often observed in stage IV (4.7% and 1.5%, respectively). In patients with stage IV adenocarcinoma who received some systemic treatment, overall survival (OS) was significantly shorter in patients with TE (median 280 days) and with DIC (72 days) than in non-TE/DIC patients (538 days). Multivariate analysis showed that older age, poor performance status, greater number of metastatic organs, no EGFR mutation/ALK fusion, presence of interstitial lung disease, and DIC were poor prognostic factors for OS. In 339 patients in stage IV, 25 (7.4%) and 21 (6.2%) patients had TE and DIC, respectively, during the course. Six patients exhibited both TE and DIC. TE was more often observed in adenocarcinoma (20 of 196 patients; 10.2%). Patients with DIC had extremely shorter survival (median 13 days) after onset. Cancer control by systemic therapy, such as chemotherapy and molecular-targeted therapy, contributed to long survival.ConclusionPatients with TE/DIC had shorter OS than patients without TE/DIC. Control of lung cancer by systemic therapy was important for longer survival after the onset of events.

show abstract

Section: Discussionmentioning

confidence: 99%

Clinical features of patients with lung cancer accompanied by thromboembolism or disseminated intravascular coagulation

Kanaji

Mizoguchi

Inoue

et al. 2018

TCRM

Self Cite

View full text Add to dashboard Cite

show abstract

“… 1 Several studies have shown that pre-existing ILD is associated with shorter survival in patients with advanced non-small cell lung cancer (NSCLC) 2 – 4 and small cell lung cancer (SCLC). 5 – 8 Idiopathic pulmonary fibrosis (IPF) is a major chronic fibrosing ILD. Several studies have reported survival in patients with SCLC and IPF.…”

Section: Introductionmentioning

confidence: 99%

Clinical features of patients with small cell lung cancer and idiopathic pulmonary fibrosis treated with chemotherapy or chemoradiotherapy

Kanaji

Shimizu

Sakai

et al. 2020

Ther Adv Respir Dis

Self Cite

View full text Add to dashboard Cite

Background: The clinical features of patients with small cell lung cancer (SCLC) and idiopathic pulmonary fibrosis (IPF) have not been fully elucidated. Patients and methods: Data on 366 patients with pathologically confirmed SCLC who had been treated with chemotherapy or chemoradiotherapy were retrospectively analyzed to investigate the clinical features of SCLC with IPF. Results: A total of 97 out of the 366 patients were diagnosed with interstitial lung disease (ILD), and 75 of them had IPF. For both the limited disease (LD) and extensive disease (ED) stages, the median progression-free survival (PFS) and overall survival (OS) were significantly shorter in the patients with IPF compared with non-ILD patients. A multivariate analysis showed that poor performance status, ED stage, and the presence of IPF were associated with shorter OS. The response rate to first-line therapy was significantly lower in patients with IPF compared with the non-ILD patients. The rate of patients receiving fewer than three cycles of first-line chemotherapy was higher in patients with IPF, which was a factor of poor survival. In LD-stage patients with IPF, chemoradiotherapy was associated with longer PFS and OS compared with chemotherapy only. Conclusion: In patients with SCLC, the presence of IPF was associated with a lower response rate as well as shorter PFS and shorter OS. There are some cases that are suitable for chemoradiotherapy, even among patients with IPF. The reviews of this paper are available via the supplemental material section.

show abstract

“…Only 10 patients with central SCLC were included in that study, and they had the same mean OS and disease-free survival (DFS) of 44.6 months, which was worse than in the peripheral SCLC patients (179.2 months and 145.3 months, respectively) (P = 0.017, P = 0.233, respectively) [35]. The 2017 study by Kanaji et al [36] found that the prognosis of central SCLC patients without surgical treatment was worse than that of peripheral SCLC patients without surgical treatment. Peripheral SCLC patients in the present study were more likely to accept subpulmonary lobectomy, especially wedge resection, and they did not undergo further anatomical lobectomy or lymphadenectomy, following to the existing SCLC treatment strategy when SCLC was con rmed from specimens harvested by wedge resection during surgery.…”

Section: Survival Analysismentioning

confidence: 99%

Clinical Outcomes and Prognosis of Small-Cell Lung Cancer(SCLC) Patients After Surgery: a Single-Centre Retrospective Cohort Study from Peking Union Medical College Hospital

Chen¹,

Liu²,

Tian³

et al. 2020

Preprint

View full text Add to dashboard Cite

Background: Small-cell lung cancer (SCLC) patients are generally not considered to be candidates for surgical intervention. The role of surgery in the multidisciplinary treatment of SCLC remains controversial. The study aims to summarize and analyse the clinical characteristics and prognosis of SCLC patients after surgical treatment and identify the related prognostic factors.Methods: The clinical data of 130 SCLC patients (99 males and 31 females) who were treated by surgery and confirmed by postoperative pathological examination in Peking Union Medical College Hospital from April 2004 to April 2019 were analysed retrospectively.Results: The median age was 60 years (30-83 years), and the median disease duration was 2 months (0.5-48 months). The patients did not have specific clinical or imaging manifestations. Postoperative pathological examination revealed that 36 patients had stage I, 22 patients had stage II, 65 patients had stage III, and seven patients had stage IV SCLC. The median overall survival time was 50 months (95% confidence interval, 10.8-89.2 months). The median survival time of stage I, II, III, and IV SCLC patients were 148 months, 42 months, 32 months, and 10 months, respectively. In patients who underwent surgical treatment, postoperative adjuvant therapy and tumour stage were two significant influencing factors of survival (Cox multivariate analysis P < 0.05).Conclusions: Surgical treatment combined with adjuvant therapy can achieve satisfactory outcomes in selected SCLC patients. Adjuvant therapy and tumour stage are independent risk factors. Surgical treatment is indicated in SCLC patients preoperatively staged as I-IIIa, and anatomical lobectomy and lymphadenectomy combined with postoperative adjuvant therapy are recommended.

show abstract

Peripheral-type small cell lung cancer is associated with better survival and higher frequency of interstitial lung disease

Cited by 28 publications

References 28 publications

Clinical features of patients with lung cancer accompanied by thromboembolism or disseminated intravascular coagulation

Clinical features of patients with lung cancer accompanied by thromboembolism or disseminated intravascular coagulation

Clinical features of patients with small cell lung cancer and idiopathic pulmonary fibrosis treated with chemotherapy or chemoradiotherapy

Clinical Outcomes and Prognosis of Small-Cell Lung Cancer(SCLC) Patients After Surgery: a Single-Centre Retrospective Cohort Study from Peking Union Medical College Hospital

Contact Info

Product

Resources

About